866-997-4948(US-Canada Toll Free)

Sezary Syndrome Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Nov 2012

Category :

Oncology

No. of Pages : 60 Pages


Global Markets Directs, \'Sezary Syndrome Pipeline Review, H2 2012\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Sezary Syndrome, complete with latest updates, and special features on late-stage and discontinued projects. 

It also reviews key players involved in the therapeutic development for Sezary Syndrome. Sezary Syndrome Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Sezary Syndrome.
  • A review of the Sezary Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Sezary Syndrome pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Sezary Syndrome.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Sezary Syndrome pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Sezary Syndrome Overview 7
Therapeutics Development 8
An Overview of Pipeline Products for Sezary Syndrome 8
Sezary Syndrome Therapeutics under Development by Companies 10
Sezary Syndrome Therapeutics under Investigation by Universities/Institutes 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Early Clinical Stage Products 13
Comparative Analysis 13
Pre-Clinical Stage Products 14
Comparative Analysis 14
Sezary Syndrome Therapeutics Products under Development by Companies 15
Sezary Syndrome Therapeutics Products under Investigation by Universities/Institutes 16
Companies Involved in Sezary Syndrome Therapeutics Development 17
Shionogi & Co., Ltd. 17
Eisai Co., Ltd. 18
Innate Pharma SA 19
Spectrum Pharmaceuticals, Inc. 20
Sezary Syndrome Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Route of Administration 23
Assessment by Molecule Type 25
Drug Profiles 27
denileukin diftitox - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
IPH-41 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
Gemcitabine + Pemetrexed Disodium - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
LBH589 + RAD001 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Campath + Fludarabine + Cyclosporine + Mycophenolate Mofetil + Peripheral Stem Cell Transplantation - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 34
alemtuzumab - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Rituximab + Carboplatin + Etoposide + Ifosfamide + Vorinostat - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 37
Treanda + Carboplatin + Rituximab + Etoposide - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 39
Carmustine + Etoposide + Cytarabine + Fludarabine Phosphate + Cyclophosphamide + Tacrolimus + Mycophenolate Mofetil + Melphalan + Filgrastim + Stem Cell Transplantation + Radiation Therapy - Drug Profile 40
Product Description 40
Mechanism of Action 41
R&D Progress 42
Carmustine + Etoposide + Cytarabine + Fludarabine Phosphate + Cyclophosphamide + Cyclosporine + Mycophenolate Mofetil + Melphalan + Therapeutic Autologous Lymphocytes + Stem Cell Transplantation + Radiation Therapy - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 44
Fludarabine Phosphate + Total-Body Irradiation + Peripheral Blood Stem Cell Transplantation + Cyclosporine + Mycophenolate Mofetil - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 47
alemtuzumab - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
lenalidomide - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
panobinostat - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Pralatrexate + Bexarotene - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
131I-BC8 (Anti-CD45) Antibody + Autologous Hematopoietic Stem Cell Transplantation - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
interferon gamma-1a - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Sezary Syndrome Therapeutics Drug Profile Updates 56
Sezary Syndrome Therapeutics Discontinued Products 57
Sezary Syndrome Therapeutics - Dormant Products 58

Appendix 59
Methodology 59
Coverage 59
Secondary Research 59
Primary Research 59
Expert Panel Validation 59
Contact Us 60
Disclaimer 60

List of Table


Number of Products Under Development for Sezary Syndrome, H2 2012 8
Products under Development for Sezary Syndrome Comparative Analysis, H2 2012 9
Number of Products under Development by Companies, H2 2012 10
Number of Products under Investigation by Universities/Institutes, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Early Clinical Stage Development, H2 2012 13
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 14
Products under Development by Companies, H2 2012 15
Products under Investigation by Universities/Institutes, H2 2012 16
Shionogi & Co., Ltd., H2 2012 17
Eisai Co., Ltd., H2 2012 18
Innate Pharma SA, H2 2012 19
Spectrum Pharmaceuticals, Inc., H2 2012 20
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Stage and Molecule Type, H2 2012 26
Sezary Syndrome Therapeutics Drug Profile Updates 56
Sezary Syndrome Therapeutics Discontinued Products 57
Sezary Syndrome Therapeutics Dormant Products 58

List of Chart


Number of Products under Development for Sezary Syndrome, H2 2012 8
Products under Development for Sezary Syndrome Comparative Analysis, H2 2012 9
Products under Development by Companies, H2 2012 10
Products under Investigation by Universities/Institutes, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Early Clinical Stage Products, H2 2012 13
Pre-Clinical Stage Products, H2 2012 14
Assessment by Monotherapy Products, H2 2012 21
Assessment by Combination Products, H2 2012 22
Assessment by Route of Administration, H2 2012 23
Assessment by Stage and Route of Administration, H2 2012 24
Assessment by Molecule Type, H2 2012 25
Assessment by Stage and Molecule Type, H2 2012 26

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *